Improved cognitive function as a consequence of hepatitis C virus treatment

HIV Medicine

Volumn 8, Issue 8, 2007, Pages 520-528

  Thein, H H ^a   Maruff, P ^b,c   Krahn, M D ^d   Kaldor, J M ^a   Koorey, D J ^e   Brew, B J ^a,f,g   Dore, G J ^a,g  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c CogState Ltd ^*  (Australia)

^d UNIVERSITY OF TORONTO   (Canada)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f Department of Neurology ^*  (Australia)

^g ST VINCENT S HOSPITAL   (Australia)

Author keywords

Antiviral therapy; HepatitisC; HIV HCV coinfection; Neuropsychological effects; Quality of life

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MANIA; MENTAL HEALTH; MOOD; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; SHORT FORM 36; SUPERINFECTION;

ADULT; ANTIVIRAL AGENTS; COGNITION DISORDERS; COGNITIVE THERAPY; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RIBAVIRIN; TREATMENT OUTCOME;

EID: 35448949150     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00505.x     Document Type: Article

References (36)

1. Braitstein P, Montessori V, Chan K et al. Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: Outcomes from a population-based cohort. AIDS Care 2005; 17: 505-515.
2. Fleming CA, Christiansen D, Nunes D et al. Health-related quality of life of patients with HIV disease: Impact of hepatitis C coinfection. Clin Infect Dis 2004; 38: 572-578.
3. Barkhuizen A, Rosen HR, Wolf S, Flora K, Benner K, Bennett RM. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: A report of 239 hepatology clinic patients. Am J Gastroenterol 1999; 94: 1355-1360.
4. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29: 264-270.
5. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-212.
6. Goh J, Coughlan B, Quinn J, O'Keane JC, Crowe J. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1999; 11: 833-838.
7. Ware JE Jr., Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999; 30: 550-555.
8. Poutiainen E, Hokkanen L, Niemi ML, Farkkila M. Reversible cognitive decline during high-dose alpha-interferon treatment. Pharmacol Biochem Behav 1994; 47: 901-905.
9. Thein HH, Maruff P, Krahn M et al. Cognitive function, mood and health-related quality of life in hepatitis C virus (HCV)-monoinfected and HIV/HCV-coinfected individuals commencing HCV treatment. HIV Med 2007; 8: 192-202.
10. Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 1991; 13: 372-374.
11. Nelson HE, Willison J. National Adult Reading Test (NART) Test Manual, 2nd edn. Berkshire: The NFER-NELSON Publishing Company Ltd, 1991.
12. Reitan RM. The validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958; 9: 127-130.
13. Cysique LA, Maruff P, Darby D, Brew BJ. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol 2006; 21: 185-194.
14. Falleti MG, Maruff P, Collie A, Darby DG, McStephen M. Qualitative similarities in cognitive impairment associated with 24 h of sustained wakefulness and a blood alcohol concentration of 0.05%. J Sleep Res 2003; 12: 265-274.
15. Darby D, Maruff P, Collie A, McStephen M. Mild cognitive impairment can be detected by multiple assessments in a single day. Neurology 2002; 59: 1042-1046.
16. Collie A, Maruff P, Darby DG, McStephen M. The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc 2003;9: 419-428.
17. Lovibond SH, Lovibond PF. Manual for the Depression Anxiety Stress Scales, 2nd edn. Sydney: Psychology Foundation Monograph, 1995.
18. Ware JE, Kosinski M. SF-36 ® Physical & Mental Health Summary Scales: A Manual for Users of Version 1, 2nd edn. Lincoln, RI: QualityMetric Incorporated, 2001.
19. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004; 13: 873-884.
20. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. New York: Academic Press, 1988.
21. Howell DC. Statistical Methods for Psychology, 5th edn. Pacific Grove: Duxbury, 2002.
22. Cysique LA, Maruff P, Brew BJ. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol 2004; 61: 1699-1704.
23. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21: 271-292.
24. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998; 51: 1115-1128.
25. Cherner M, Letendre S, Heaton RK et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 2005; 64: 1343-1347.
26. Letendre SL, Cherner M, Ellis RJ et al. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS 2005; 19 (Suppl. 3): S72-S78.
27. Ryan EL, Morgello S, Isaacs K, Naseer M, Gerits P. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 2004; 62: 957-962.
28. Brew BJ. HIV Neurology. New York: Oxford University Press, 2001.
29. Heaton RK, Grant I, Butters N et al. The HNRC 500 -neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1995; 1: 231-251.
30. Kraus MR, Schafer A, Wissmann S, Reimer P, Scheurlen M. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clin Pharmacol Ther 2005; 77: 90-100.
31. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 2000; 157: 867-876.
32. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41: 672-676.
33. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998; 25: 39-47.
34. Kanwal F, Gralnek IM, Hays RD et al. Impact of chronic viral hepatitis on Health-Related Quality of Life in HIV: Results from a Nationally Representative Sample. Am J Gastroenterol 2005; 100: 1984-1994.
35. McHutchison JG, Ware JE Jr., Bayliss MS et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 140-147.
36. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology 2005; 41: 790-800.